ARTICLE | Product R&D
BlueRock’s PD purity play
Why BlueRock’s iPS cells could fare better in Parkinson’s than fetal transplants
February 1, 2019 12:53 AM UTC
Regenerative medicine company BlueRock is gearing up to submit its first IND this year, banking on its approach to Parkinson’s disease to overcome the legacy of failed fetal transplants by offering a more stable and pure supply of dopaminergic neurons.
BlueRock splashed onto the scene at the end of 2016 when Bayer AG and Versant Ventures teamed up to launch the biotech with a record-setting $225 million series A financing (see “Starting Up Stem Cells”). ...